David R Costa

US Patent:

20060117630, Jun 8, 2006

Filed:

Nov 29, 2005

Appl. No.:

11/289780

Inventors:

Richard Raia - Lexington MA, US
Lee Porter - Keene NH, US
David Costa - Rowley MA, US

International Classification:

G09F 7/22
G09F 3/20

US Classification:

040658000, 040617000

Abstract:

The present invention is directed to an improved card holder comprising a pair of parallel arms connected to one another in a spaced apart relationship. A resilient gripping material is included, preferably as finger-like appendages, on at least a portion of the inside surfaces of the spaced apart arms, such that when an ID card or the like is inserted into the space between the arms, the resilient gripping material compresses sufficiently to allow insertion, but also provides a secure gripping for retention of the ID card or the like, thereby preventing slippage of the card from the holder. To remove the inserted ID card or the like, force adequate to overcome the gripping is applied to the card, thereby permitting removal of the card from the holder. The amount of force needed will vary with the nature and thickness of the card, the gripping material, and the like. The holding power will likewise vary.

US Patent:

20220403418, Dec 22, 2022

Filed:

Nov 25, 2020

Appl. No.:

17/756104

Inventors:

- Austin TX, US
Rafet BASAR - Houston TX, US
Emily ENSLEY - Houston TX, US
David MARIN COSTA - Houston TX, US

International Classification:

C12N 15/90
C12N 5/0781
A61K 35/17
C07K 14/705
C07K 14/725

Abstract:

Embodiments of the disclosure encompass methods and compositions for producing engineered B cells. The disclosure concerns large-scale processes for producing B cells that are engineered to have disruption of expression of one or more genes using CRISPR and also express at least one heterologous antigen receptor. Specific embodiments include particular parameters for the process.

US Patent:

20220389383, Dec 8, 2022

Filed:

Nov 25, 2020

Appl. No.:

17/755887

Inventors:

- Austin TX, US
Rafet BASAR - Houston TX, US
May DAHER - Houston TX, US
David MARIN COSTA - Houston TX, US

International Classification:

C12N 5/0783
A61K 35/17
A61P 35/00
C12N 15/113

Abstract:

Embodiments of the disclosure encompass methods and compositions for producing engineered natural killer (NK) cells. The disclosure concerns large-scale processes for producing NK cells that are engineered to have disruption of expression of one or more genes, such as using CRISPR, and also engineered express at least one heterologous antigen receptor. Specific embodiments include particular parameters for the process.

US Patent:

20220378739, Dec 1, 2022

Filed:

Nov 25, 2020

Appl. No.:

17/755881

Inventors:

- Austin TX, US
Mayra SHANLEY - Houston TX, US
Elizabeth SHPALL - Houston TX, US
David MARIN COSTA - Houston TX, US
Rafet BASAR - Houston TX, US
Hila SHAIM - Houston TX, US

International Classification:

A61K 31/395
A61K 35/17
C12N 5/0783

Abstract:

Embodiments of the disclosure provide methods and compositions that facilitate cancer treatment including at least because they concern therapies that circumvent the tumor microenvironment. In specific embodiments, compositions are utilized for therapy that utilize NK cells that are protected from the direct inhibition of their activity (using TGF-beta inhibitors) and/or that are indirectly protected from TGF-beta (using integrin inhibitors). In specific embodiments, the NK cells have deficient expression and/or activity for TGF-beta Receptor 2 and/or glucocorticoid receptor.

US Patent:

20220370500, Nov 24, 2022

Filed:

Sep 15, 2020

Appl. No.:

17/761190

Inventors:

- Austin TX, US
David MARIN COSTA - Houston TX, US

Assignee:

BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM - Austin TX

International Classification:

A61K 35/17
A61P 35/00

Abstract:

Embodiments of the disclosure include methods and compositions related to targeting of BCMA-expressing cells by NK cells specifically engineered to bind the BCMA antigen. In particular embodiments, NK cells that are manipulated to expressing BCMA-targeting chimeric antigen receptors (CARs) are utilized to target cancers that express BCMA. In certain embodiments, vectors that express the BCMA-targeting CARs also express particular suicide genes and/or particular cytokines.

US Patent:

20220288121, Sep 15, 2022

Filed:

Aug 25, 2020

Appl. No.:

17/638601

Inventors:

- Austin TX, US
Enli LIU - Houston TX, US
Elizabeth SHPALL - Houston TX, US
Rafet BASAR - Houston TX, US
David MARIN COSTA - Houston TX, US

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

A61K 35/17
A01N 1/02
C12N 5/0783
A61K 35/545
A61K 35/28
A61K 35/15

Abstract:

Provided herein are cryopreservation compositions and methods for cells of any kind, including for cells for adoptive cell therapy that are off-the-shelf cells. The cells for cryopreservation may be expanding NK cells expressing chimeric antigen receptors. In specific cases, the cryopreservation media comprises a cryoprotectant, such as DMSO, glycerol or hydroxyethol starch; serum or a non-serum alternative, such as platelet lysate; and one or more cytokines that are either natural, modified, synthetic, or recombinant.

US Patent:

20230074303, Mar 9, 2023

Filed:

Mar 25, 2021

Appl. No.:

17/904408

Inventors:

- Austin TX, US
Mayra SHANLEY - Houston TX, US
David MARIN COSTA - Houston TX, US
Hila SHAIM - Houston TX, US
Elizabeth SHPALL - Houston TX, US

International Classification:

A61K 35/17
A61P 35/00
A61K 45/06
C07K 14/54
A61K 38/20

Abstract:

Embodiments of the disclosure encompass compositions comprising immune effector cells, such as natural killer (NK) cells, where the cells comprise one or more exogenously provided interleukins (IL), and wherein the cell optionally comprises one or more engineered receptors. In specific embodiments, the IL is not IL-15, and is IL-12, IL-21, or both. The NK cells may be utilized for treatment of cancer of any kind, including at least glioblastoma.